4.7 Article

Soluble CD40 ligand induces endothelial dysfunction in human and porcine coronary artery endothelial cells

期刊

BLOOD
卷 112, 期 8, 页码 3205-3216

出版社

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2008-03-143479

关键词

-

资金

  1. National Institutes of Health [DE15543, AT003094, EB-002436, HL083471]
  2. Department of Surgery, Baylor College of Medicine

向作者/读者索取更多资源

The purpose of this study was to determine the effects and mechanisms of sCD40L on endothelial dysfunction in both human coronary artery endothelial cells (HCAECs) and porcine coronary artery rings. HCAECs treated with sCD40L showed significant reductions of endothelial nitric oxide synthase (eNOS) mRNA and protein levels, eNOS mRNA stability, eNOS enzyme activity, and cellular NO levels, whereas superoxide anion (O-2(-)) production was significantly increased. sCD40L enhanced eNOS mRNA 3'UTR binding to cytoplasmic molecules and induced a unique expression pattern of 95 microRNAs. sCD40L significantly decreased mitochondrial membrane potential, and catalase and SOD activities, whereas it increased NADPH oxidase (NOX) activity. sCD40L increased phosphorylation of MAPKs p38 and ERK1/2 as well as I kappa B alpha and enhanced NF-kappa B nuclear translocation. In porcine coronary arteries, sCD40L significantly decreased endothelium-dependent vasorelaxation and eNOS mRNA levels, whereas it increased O-2-levels. Antioxidant seleno-L-methionine; chemical inhibitors of p38, ERK1/2, and mitochondrial complex II; as well as dominant negative mutant forms of I kappa B alpha and NOX4 effectively blocked sCD40L-induced eNOS down-regulation in HCAECs. Thus, sCD40L reduces eNOS levels, whereas it increases oxidative stress through the unique molecular mechanisms involving eNOS mRNA stability, 3'UTR-binding molecules, microRNAs, mitochondrial function, ROS-related enzymes, p38, ERK1/2, and NF-kappa B signal pathways in endothelial cells.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Immunology

Improved Multiplex Immunohistochemistry for Immune Microenvironment Evaluation of Mouse Formalin-Fixed, Paraffin-Embedded Tissues

Noah Sorrelle, Debolina Ganguly, Adrian T. A. Dominguez, Yuqing Zhang, Huocong Huang, Lekh N. Dahal, Natalie Burton, Arturas Ziemys, Rolf A. Brekken

JOURNAL OF IMMUNOLOGY (2019)

Article Medicine, Research & Experimental

Targeting TGFβR2-mutant tumors exposes vulnerabilities to stromal TGFβ blockade in pancreatic cancer

Huocong Huang, Yuqing Zhang, Valerie Gallegos, Noah Sorrelle, Mohamed Medhat Zaid, Jason Toombs, Wenting Du, Steven Wright, Moriah Hagopian, Zhaoning Wang, Abdel Nasser Hosein, Adwait Amod Sathe, Chao Xing, Eugene J. Koay, Kyla E. Driscoll, Rolf A. Brekken

EMBO MOLECULAR MEDICINE (2019)

Article Oncology

AXL Is a Key Factor for Cell Plasticity and Promotes Metastasis in Pancreatic Cancer

Wenting Du, Natalie Z. Phinney, Huocong Huang, Zhaoning Wang, Jill Westcott, Jason E. Toombs, Yuqing Zhang, Muhammad S. Beg, Thomas M. Wilkie, James B. Lorens, Rolf A. Brekken

Summary: The study found that AXL is highly expressed in PDA tumor cells and correlates with markers of epithelial-to-mesenchymal transition. AXL deficiency extended survival, reduced primary and metastatic burden, and enhanced sensitivity to gemcitabine in mice. AXL-positive poorly differentiated tumor cells were crucial for PDA progression and metastasis, highlighting the potential of AXL as a therapeutic target.

MOLECULAR CANCER RESEARCH (2021)

Review Oncology

Perspectives on Hypoxia Signaling in Tumor Stroma

Yuqing Zhang, Morgan Coleman, Rolf A. Brekken

Summary: Hypoxia is a common feature of solid tumors that promotes tumor progression and metastasis. Hypoxia, mainly mediated by the HIF family, leads to tumor cell migration, proliferation, metabolic changes, and therapy resistance. Additionally, hypoxia affects various cellular and non-cellular compartments in the tumor stroma, including disordered tumor vasculature and ECM homeostasis. Hypoxia also has complex and sometimes contradictory effects on immune cell function, contributing to an immunosuppressive environment.

CANCERS (2021)

Article Oncology

AXL Inhibitor TP-0903 Reduces Metastasis and Therapy Resistance in Pancreatic Cancer

Yuqing Zhang, Emily N. Arner, Ali Rizvi, Jason E. Toombs, Huocong Huang, Steven L. Warner, Jason M. Foulks, Rolf A. Brekken

Summary: Pancreatic cancer is a major cause of cancer-related deaths in the US, with resistance to therapy and immunosuppressive microenvironment being major challenges. The AXL inhibitor TP-0903 shows anti-tumor and sensitizing effects in preclinical models of pancreatic cancer, leading to improved prognosis and immune activation.

MOLECULAR CANCER THERAPEUTICS (2022)

Article Medicine, Research & Experimental

VEGFR2 activity on myeloid cells mediates immune suppression in the tumor microenvironment

Yuqing Zhang, Huocong Huang, Morgan Coleman, Arturas Ziemys, Purva Gopal, Syed M. Kazmi, Rolf A. Brekken

Summary: Studies have shown that VEGF induces an immunosuppressive phenotype in VEGFR2* myeloid cells, while VEGF blockade inhibits this phenotype and enhances T cell activation, improving the efficacy of immune checkpoint blockade. This indicates the potential of VEGF inhibition in potentiating immune therapy for cancer.

JCI INSIGHT (2021)

Article Oncology

Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer

Huocong Huang, Zhaoning Wang, Yuqing Zhang, Rachana N. Pradhan, Debolina Ganguly, Raghav Chandra, Gilbert Murimwa, Steven Wright, Xiaowu Gu, Ravikanth Maddipati, Soren Mueller, Shannon J. Turley, Rolf A. Brekken

Summary: Recent studies have identified a unique population of cancer-associated fibroblasts (apCAFs) derived from mesothelial cells, which play a critical role in pancreatic cancer progression. These apCAFs directly induce naive CD4(+) T cells to differentiate into regulatory T cells (Tregs) in an antigen-specific manner.

CANCER CELL (2022)

Editorial Material Oncology

Are TEMs Canceled? Questioning the Functional Relevance of Tie2-Expressing Macrophages

Yuqing Zhang, Rolf A. Brekken

Summary: The study challenges the functional significance of Tie2-expressing macrophages in tumor angiogenesis and relapse after chemotherapy, highlighting the need for reconsideration of Tie2 as a therapeutic target or prognostic indicator.

CANCER RESEARCH (2022)

Review Cell Biology

Direct and indirect regulation of the tumor immune microenvironment by VEGF

Yuqing Zhang, Rolf A. Brekken

Summary: VEGF is a key factor in tumor angiogenesis and also contributes to tumor immunosuppression. It interferes with immune cell trafficking indirectly through VEGFR activation on endothelial cells and has direct effects on various immune cell types. Targeting VEGF/VEGFRs has shown efficacy in alleviating tumor-associated immunosuppression and has been combined with immunotherapies.

JOURNAL OF LEUKOCYTE BIOLOGY (2022)

Meeting Abstract Oncology

Targeting Rab7mediated STING degradation to amplify therapeutic STING agonism in TNBC

Yuqing Zhang, Jessica L. Ritter, Tran C. Thai, Deborah A. Dillon, David A. Barbie, Thanh U. Barbie

CANCER RESEARCH (2023)

Meeting Abstract Oncology

Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer.

Huocong Huang, Zhaoning Wang, Yuqing Zhang, Rachana N. Pradhan, Debolina Ganguly, Raghav Chandra, Gilbert Murimwa, Steven Wright, Xiaowu Gu, Ravikanth Maddipati, Soren Muller, Shannon J. Turley, Rolf A. Brekken

CANCER RESEARCH (2022)

Meeting Abstract Oncology

Selective inhibition of VEGF binding to VEGFR2 promotes an immune stimulatory microenvironment in murine models of breast cancer.

Yuqing Zhang, Huocong Huang, Noah Sorrelle, Rolf Brekken

CANCER IMMUNOLOGY RESEARCH (2021)

Meeting Abstract Oncology

Selective inhibition of VEGF binding to VEGFR2 promotes an immune stimulatory microenvironment in murine models of breast cancer.

Yuqing Zhang, Huocong Huang, Noah Sorrelle, Rolf Brekken

CANCER IMMUNOLOGY RESEARCH (2021)

Meeting Abstract Oncology

Immune toxicity and flow cytometry of circulating blood cells in cancer patients receiving immune therapy.

Saad A. Khan, Noah Sorrelle, Rolf A. Brekken, Rong Lu, Mitchell S. von Itzstein, Donglu Xie, David Hsieh, Yvonne Gloria-McCutchen, Jessica Saltarski, Mary Watters, Benjamin Aaron Bleiberg, Vinita Popat, Murtaza Ahmed, Yuqing Zhang, Farjana Fattah, Shaheen Khan, Jason Park, David E. Gerber

JOURNAL OF CLINICAL ONCOLOGY (2020)

Meeting Abstract Oncology

Axl inhibitor TP-0903 augments chemo- and immunotherapy efficacy in pancreatic cancer

Yuqing Zhang, Emily N. Arner, Jason E. Toombs, Jason M. Foulks, Steven L. Warner, Rolf A. Brekken

MOLECULAR CANCER THERAPEUTICS (2019)

暂无数据